Search - tctmd.com

Displaying 101 - 120 of 334

Sort: Relevancy | Date

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

March 14, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

News Daily News

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

Yael L. Maxwell

February 21, 2023

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

February 17, 2023

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

February 02, 2023

PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures

News Daily News

PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures

January 18, 2023

CT Angiography Is Increasing in England, but Downstream Tests Are Not

News Daily News

CT Angiography Is Increasing in England, but Downstream Tests Are Not

Michael O'Riordan

January 12, 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

December 16, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

News Daily News

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

Michael O'Riordan

September 26, 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.